PE20171319A1 - Composiciones dispersables - Google Patents

Composiciones dispersables

Info

Publication number
PE20171319A1
PE20171319A1 PE2017001255A PE2017001255A PE20171319A1 PE 20171319 A1 PE20171319 A1 PE 20171319A1 PE 2017001255 A PE2017001255 A PE 2017001255A PE 2017001255 A PE2017001255 A PE 2017001255A PE 20171319 A1 PE20171319 A1 PE 20171319A1
Authority
PE
Peru
Prior art keywords
composition
refers
layer
dispersible compositions
dispersible
Prior art date
Application number
PE2017001255A
Other languages
English (en)
Inventor
Manish Kumar Gupta
Shripad Wasudeo Marathe
Kaustubh Ramesh Tambwekar
Shreedevi Velayudhan Nair
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20171319A1 publication Critical patent/PE20171319A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Lubricants (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Referido a una composicion dispersable que comprende: fumarato de bedaquilina; una capa intragranular; y una capa extragranular, donde ambas capas comprenden un excipiente/diluyente no soluble tal como celulosa microcristalina. Ademas, dicha composicion comprende disgregantes, deslizantes, humectantes o tensioactivos, aglutinantes o polimeros, lubricantes y disolventes. Tambien se refiere a un procedimiento de preparacion. Dicha composicion es util en el tratamiento de la tuberculosis, sobretodo en poblaciones pediatricas y geriatricas.
PE2017001255A 2015-01-27 2016-01-26 Composiciones dispersables PE20171319A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN264MU2015 2015-01-27

Publications (1)

Publication Number Publication Date
PE20171319A1 true PE20171319A1 (es) 2017-09-07

Family

ID=55229712

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017001255A PE20171319A1 (es) 2015-01-27 2016-01-26 Composiciones dispersables

Country Status (29)

Country Link
US (2) US20180000810A1 (es)
EP (1) EP3250182B1 (es)
JP (3) JP7291458B2 (es)
KR (1) KR102631986B1 (es)
CN (2) CN107205945A (es)
AU (2) AU2016212116B2 (es)
CA (1) CA2973301A1 (es)
CY (1) CY1126107T1 (es)
DK (1) DK3250182T3 (es)
EA (1) EA201791701A1 (es)
ES (1) ES2948805T3 (es)
FI (1) FI3250182T3 (es)
HK (1) HK1243644A1 (es)
HR (1) HRP20230616T1 (es)
HU (1) HUE062481T2 (es)
IL (2) IL310920A (es)
LT (1) LT3250182T (es)
MA (1) MA41411B1 (es)
MD (1) MD3250182T2 (es)
MX (1) MX2017009681A (es)
PE (1) PE20171319A1 (es)
PH (1) PH12017501331A1 (es)
PL (1) PL3250182T3 (es)
PT (1) PT3250182T (es)
RS (1) RS64308B1 (es)
SG (1) SG11201705944TA (es)
SI (1) SI3250182T1 (es)
UA (1) UA126891C2 (es)
WO (1) WO2016120258A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
SI3651736T1 (sl) * 2017-07-14 2021-11-30 Janssen Pharmaceutica Nv Formulacije z dolgim delovanjem
EP3773731A1 (en) * 2018-04-05 2021-02-17 Cipla Limited Pharmaceutical formulations
US11291654B2 (en) * 2018-09-13 2022-04-05 Syneurx International (Taiwan) Corp. Formulations of cycloserine compounds and applications thereof
WO2020123336A1 (en) * 2018-12-13 2020-06-18 Qrumpharma Inc. Compositions of bedaquiline, combinations comprising them, processes for their preparation, uses and methods of treatment comprising them
JP2022516671A (ja) * 2019-01-09 2022-03-01 ヤンセン ファーマシューティカ エヌ．ベー． 非結核性抗酸菌症の処置における組合せ
WO2021257461A1 (en) * 2020-06-15 2021-12-23 Mylan Laboratories Limited Combination antibacterial composition and method for antibacterial therapy
WO2021257466A1 (en) * 2020-06-15 2021-12-23 The Global Alliance For Tb Drug Development, Inc. Combination antibacterial composition and method for antibacterial therapy
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
KR102478006B1 (ko) 2020-12-03 2022-12-15 정승찬 자동차 긴급 제동장치
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
GB202211231D0 (en) 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ538391A (en) 2002-07-25 2005-10-28 Janssen Pharmaceutica Nv Quinoline derivatives and their use as mycobacterial inhibitors
KR101371653B1 (ko) 2004-05-28 2014-03-07 얀센 파마슈티카 엔.브이. 약물 내성 마이코박테리아 질환 치료를 위한 치환된 퀴놀린유도체의 용도
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
KR101712835B1 (ko) * 2005-05-25 2017-03-07 얀센 파마슈티카 엔.브이. (알파 ｓ, 베타 ｒ)-6-브로모-알파-(2-(디메틸아미노)에틸)-2-메톡시-알파-1-나프탈레닐-베타-페닐-3-퀴놀린에탄올의 제조 방법
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
AU2007283196A1 (en) * 2006-08-10 2008-02-14 Cipla Limited Antiretroviral solid oral composition
UA97813C2 (uk) 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
EP2271320A4 (en) * 2008-04-02 2011-05-18 Reddys Lab Ltd Dr PHARMACEUTICAL RALOXIFY FORMULATIONS
AU2009288820A1 (en) 2008-09-03 2010-03-11 Pfizer Inc. Combination therapy for tuberculosis
US20120207838A1 (en) * 2011-02-10 2012-08-16 Perricone Nicholas V Treatment of Psoriasis Using Oral Dosage Forms of Nitrone Spin Traps
WO2013153162A1 (en) * 2012-04-11 2013-10-17 Sandoz Ag Polymorph of rilpivirine hydrochloride
US20140075692A1 (en) * 2012-09-18 2014-03-20 Unger Marketing International, Llc. Multiuse cleaning tool handle
MX2015006217A (es) * 2012-11-19 2015-11-16 Azanta As Tableta dispersable.

Also Published As

Publication number Publication date
RS64308B1 (sr) 2023-07-31
EP3250182B1 (en) 2023-04-26
HUE062481T2 (hu) 2023-11-28
JP2022176982A (ja) 2022-11-30
US20180000810A1 (en) 2018-01-04
JP2018502928A (ja) 2018-02-01
SG11201705944TA (en) 2017-08-30
AU2016212116B2 (en) 2021-07-15
AU2016212116A1 (en) 2017-07-27
PT3250182T (pt) 2023-07-07
ES2948805T3 (es) 2023-09-19
SI3250182T1 (sl) 2023-08-31
WO2016120258A1 (en) 2016-08-04
JP7291458B2 (ja) 2023-06-15
KR20170106447A (ko) 2017-09-20
DK3250182T3 (da) 2023-06-26
IL253626B1 (en) 2024-04-01
US20220331307A1 (en) 2022-10-20
MA41411B1 (fr) 2023-07-31
IL310920A (en) 2024-04-01
PL3250182T3 (pl) 2023-07-31
MA41411A (fr) 2017-12-05
JP2021098706A (ja) 2021-07-01
HRP20230616T1 (hr) 2023-09-29
CY1126107T1 (el) 2023-11-15
MD3250182T2 (ro) 2023-09-30
AU2021204135B2 (en) 2023-10-05
EA201791701A1 (ru) 2017-11-30
EP3250182A1 (en) 2017-12-06
BR112017015784A2 (pt) 2018-03-27
UA126891C2 (uk) 2023-02-22
MX2017009681A (es) 2017-10-18
FI3250182T3 (fi) 2023-06-28
HK1243644A1 (zh) 2018-07-20
IL253626A0 (en) 2017-09-28
CN114129526A (zh) 2022-03-04
CN107205945A (zh) 2017-09-26
KR102631986B1 (ko) 2024-01-30
PH12017501331A1 (en) 2017-12-11
CA2973301A1 (en) 2016-08-04
LT3250182T (lt) 2023-07-10
AU2021204135A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
PE20171319A1 (es) Composiciones dispersables
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
CL2016002414A1 (es) Compuestos derivados de nucleosidos, inhibidores de la transcriptasa inversas composición farmacéutica que los comprende y su uso en el tratamiento de una infección por vih. pct
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
NZ733174A (en) Quinazoline derivatives used to treat hiv
NZ728072A (en) Modulators of toll-like receptors for the treatment of hiv
CL2016000698A1 (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
NZ735575A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NZ732391A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2017037594A3 (zh) 用于减少局部脂肪的医药组成物及其用途
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX2016004492A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana (vih).
IN2013MU03583A (es)
PH12018501237A1 (en) Isoindole compounds
PH12017500569A1 (en) Compositions and methods for the treatment and prophylaxis of surgical site infections
NZ733670A (en) Insulin glargine/lixisenatide fixed ratio formulation
IN2014MU01042A (es)
CR20180091A (es) 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del vih
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
WO2016086153A3 (en) Use of hsp90 inhibitors for the treatment of hiv infections and aids
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
PH12014502834B1 (en) Pharmaceutical form for extended release of active substances
EA201692518A2 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила